The invention provides a mix or a nutritional composition comprising a probiotic Lactobacillus Fermentum CECT-5716 and a nutrient selected from the group consisting of beta-carotene, fiber, Vitamin C, Folate, Vitamin B1, Vitamin B2, Vitamin B5, Vitamin B6, Vitamin B12 and Potassium, or combination of two of more thereof, for use in treating or preventing mastitis, especially subclinical mastitis, in a subject, preferably a pregnant or lactating woman.

Disclosed herein are formulations with improved stability or reduced viscosity that comprise a therapeutic protein and a lyo-enhancing excipient, wherein the improved stability formulation is characterized by improved stability in comparison to a control formulation otherwise identical to the stability-enhanced formulation but lacking the lyo-enhancing excipient, and the reduced viscosity formulation is characterized by reduced viscosity in comparison to a control formulation otherwise identical to the reduced viscosity formulation but lacking the lyo-enhancing excipient. Further disclosed herein are methods of improving stability of therapeutic formulations, reducing viscosity of therapeutic formulations, or improving parameters of lyophilization processes.

Methods of producing multiple protein products from blood-based materials including alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins are described herein. The inventive methods include steps of fractionation that utilize a combination of salt and organic solvent. Advantageously, the inventive methods are simple and produce alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins in high yields. The sequence of process steps can be selected to obtain multiple products from various in-process materials, such as supernatants, pastes, chromatography flow-though, and chromatography washes.

Methods of producing multiple protein products from blood-based materials including alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins are described herein. The inventive methods include steps of fractionation that utilize a combination of salt and organic solvent. Advantageously, the inventive methods are simple and produce alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins in high yields. The sequence of process steps can be selected to obtain multiple products from various in-process materials, such as supernatants, pastes, chromatography flow-though, and chromatography washes.

The present invention relates to use of an α-lactalbumin enriched whey protein extract as a source of cholesterol in a synthetic nutritional composition for an infant or child wherein, the α-lactalbumin enriched (WPE) is obtained by a process comprising steps of (i) acidifying a whey protein product to pH 4 or below; (ii) forming a low calcium whey protein product by concentrating the proteins in the acidified whey protein until the calcium to protein ratio is less than about 0.001 and, (iii) Precipitating α-lactalbumin from the low-calcium whey protein product, wherein said precipitating step includes the sub-steps of: (a) diluting the low-calcium whey protein product, (b) adjusting the pH of the diluted low-calcium whey protein product to between 4 and 5 to form a precipitate and soluble proteins, and (c) Separating the precipitate proteins from the soluble proteins; wherein the WPE is added to said composition in an effective amount sufficient to ensure that said synthetic nutritional composition has a final concentration of cholesterol found in human breast milk.

The present invention relates to use of an α-lactalbumin enriched whey protein extract as a source of cholesterol in a synthetic nutritional composition for an infant or child wherein, the α-lactalbumin enriched (WPE) is obtained by a process comprising steps of (i) acidifying a whey protein product to pH 4 or below; (ii) forming a low calcium whey protein product by concentrating the proteins in the acidified whey protein until the calcium to protein ratio is less than about 0.001 and, (iii) Precipitating α-lactalbumin from the low-calcium whey protein product, wherein said precipitating step includes the sub-steps of: (a) diluting the low-calcium whey protein product, (b) adjusting the pH of the diluted low-calcium whey protein product to between 4 and 5 to form a precipitate and soluble proteins, and (c) Separating the precipitate proteins from the soluble proteins; wherein the WPE is added to said composition in an effective amount sufficient to ensure that said synthetic nutritional composition has a final concentration of cholesterol found in human breast milk.

The present invention relates to a process of preparation of a biomaterial comprising the steps of: a) Preparing a solution comprising at least one protein having a solubility in water superior or equal to about 10 mg/mL and at least one salt having solubility in water superior or equal to about 500 mg/mL, b) Evaporating the solution obtained in step a) as is, as a foam obtained by foaming the solution obtained in step a), or as a mixture thereof, at a temperature comprised of from 4 to 50° C. in atmospheric pressure or at lower temperatures under vacuum or at a pressure lower than atmospheric pressure, until the formation of two non-miscible phases or until obtaining a substantially dry solid, thereby obtaining a biomaterial.

The present invention also relates to a biomaterial obtainable by the process, and to the use of the biomaterial as a support for in vitro tissue engineering and/or for in vitro cell culture and in vitro expansion and/or as an implantable medical device, or as a drug.

The present invention discloses an aqueous pharmaceutical composition containing a protein in which serum albumin and growth hormone are linked. The aqueous pharmaceutical composition contains, as an active ingredient, a fusion protein of human serum albumin and human growth hormone; the concentration of the fusion protein is 10-100 mg/mL; the concentration of sucrose is 10-150 mg/mL; the concentration of a nonionic surfactant is 0.15-10 mg/mL; the concentration of a preservative is 0.5-12 mg/mL; the concentration of a buffer is 1-30 mM; and the pH is 5.0-8.0.

The present invention provides a composition comprising dendritic cells loaded with hHsp60sp, which dendritic cells are from a subject and have been fixed with paraformaldehyde (PFA). The subject may suffer from an autoimmune disease. Also provided are a method for preparing the composition; recombinant human cells comprising a heterologous gene encoding a fusion protein of HLA-E and hHsp60sp or B7sp, and expressing the fusion protein on the surface of the cells; a method for determining a percentage of maximum inhibition of testing the function of the HLA-E restricted CD8+ Treg cells from a subject, determining whether HLA-E restricted CD8+ Treg cells freshly isolated from a subject are defective, or determining whether defective HLA-E restricted CD8+ Treg cells from a subject are correctable; and a method for correcting defective HLA-E restricted CD8+ Treg cells, treating type 1 diabetes (T1D), or treating multiple sclerosis (MS).

This document relates to non-covalently bound complexes comprising cabazitaxel and human serum albumin. This document also relates to compositions comprising non-covalently bound complexes comprising cabazitaxel and human serum albumin. This document also relates to compositions comprising cabazitaxel and human serum albumin. This document also relates to compositions consisting essentially of cabazitaxel and human serum albumin.